Geron Cellvein Launches PDRN-Based Skin Regeneration "RejuMedi Cream" ... Full-Scale Entry into OTC Market

On February 2, Geron Cellvein, a company specializing in the production of prescription pharmaceuticals, announced the launch of "RejuMedi Cream," an over-the-counter (OTC) skin regeneration medicine based on Polydeoxyribonucleotide (PDRN), as it aims to expand into the OTC pharmaceutical market.

The newly released "RejuMedi Cream" has obtained manufacturing and sales approval from the Ministry of Food and Drug Safety and has been officially launched in the domestic market, proving its pharmaceutical-level safety and efficacy.

The product is manufactured using Geron Cellvein's proprietary patented technology, "Prism Technology Nano PDRN," as its main ingredient, and is produced according to the strict Korea Good Manufacturing Practice (KGMP) standards for pharmaceutical companies, ensuring it can be safely used even on sensitive skin.

In particular, the main ingredient, PDRN, is widely used in the fields of regenerative medicine and dermatological research. "RejuMedi Cream" is an OTC medicine used for ulcers and wounds caused by nutritional deficiencies or disorders in the skin and connective tissue, providing regenerative effects for damaged skin areas.

The product comes in two sizes, 10g and 20g, and the company plans to expand consumer access through a nationwide pharmacy distribution network.

Kim Deokgyu, CEO of Geron Cellvein, stated, "Based on our extensive research capabilities accumulated over the years in PDRN, we expect to meet the market demand for managing damaged skin areas," adding, "We will continue to broaden the range of choices for consumers who need skin care, based on the safety and quality of our pharmaceuticals."

He further added, "With the launch of RejuMedi Cream, we plan to expand our pharmacy distribution network nationwide and strengthen our position as a global biotechnology company by offering a diverse lineup utilizing our core ingredient, PDRN."

This content was produced with the assistance of AI translation services.